vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $47.7M, roughly 1.5× IRONWOOD PHARMACEUTICALS INC). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs -4.8%, a 44.6% gap on every dollar of revenue. On growth, Apollo Commercial Real Estate Finance, Inc. posted the faster year-over-year revenue change (4.0% vs -47.3%). Over the past eight quarters, Apollo Commercial Real Estate Finance, Inc.'s revenue compounded faster (-4.6% CAGR vs -20.2%).
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
ARI vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $47.7M |
| Net Profit | $29.2M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | 39.7% | 14.3% |
| Net Margin | 39.9% | -4.8% |
| Revenue YoY | 4.0% | -47.3% |
| Net Profit YoY | -28.2% | -200.9% |
| EPS (diluted) | $0.19 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $73.3M | $47.7M | ||
| Q3 25 | $61.6M | $122.1M | ||
| Q2 25 | $70.9M | $85.2M | ||
| Q1 25 | $65.8M | $41.1M | ||
| Q4 24 | $70.5M | $90.5M | ||
| Q3 24 | $71.6M | $91.6M | ||
| Q2 24 | $81.1M | $94.4M | ||
| Q1 24 | $80.5M | $74.9M |
| Q4 25 | $29.2M | $-2.3M | ||
| Q3 25 | $50.8M | $40.1M | ||
| Q2 25 | $20.7M | $23.6M | ||
| Q1 25 | $26.0M | $-37.4M | ||
| Q4 24 | $40.7M | $2.3M | ||
| Q3 24 | $-91.5M | $3.6M | ||
| Q2 24 | $35.8M | $-860.0K | ||
| Q1 24 | $-104.5M | $-4.2M |
| Q4 25 | 39.7% | 14.3% | ||
| Q3 25 | 82.8% | 61.8% | ||
| Q2 25 | 29.4% | 53.2% | ||
| Q1 25 | 39.7% | -70.7% | ||
| Q4 24 | 57.9% | 34.8% | ||
| Q3 24 | -127.8% | 28.0% | ||
| Q2 24 | 44.2% | 26.5% | ||
| Q1 24 | -129.6% | 14.7% |
| Q4 25 | 39.9% | -4.8% | ||
| Q3 25 | 82.4% | 32.8% | ||
| Q2 25 | 29.3% | 27.7% | ||
| Q1 25 | 39.5% | -90.9% | ||
| Q4 24 | 57.7% | 2.5% | ||
| Q3 24 | -127.9% | 4.0% | ||
| Q2 24 | 44.1% | -0.9% | ||
| Q1 24 | -129.8% | -5.6% |
| Q4 25 | $0.19 | $0.01 | ||
| Q3 25 | $0.34 | $0.23 | ||
| Q2 25 | $0.12 | $0.14 | ||
| Q1 25 | $0.16 | $-0.23 | ||
| Q4 24 | $0.25 | $0.03 | ||
| Q3 24 | $-0.69 | $0.02 | ||
| Q2 24 | $0.23 | $-0.01 | ||
| Q1 24 | $-0.76 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $-261.8M |
| Total Assets | $9.9B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $139.8M | $215.5M | ||
| Q3 25 | $245.9M | $140.4M | ||
| Q2 25 | $177.6M | $92.9M | ||
| Q1 25 | $166.4M | $108.5M | ||
| Q4 24 | $317.4M | $88.6M | ||
| Q3 24 | $194.3M | $88.2M | ||
| Q2 24 | $174.7M | $105.5M | ||
| Q1 24 | $161.2M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $1.9B | $-261.8M | ||
| Q3 25 | $1.9B | $-264.2M | ||
| Q2 25 | $1.8B | $-308.2M | ||
| Q1 25 | $1.9B | $-334.1M | ||
| Q4 24 | $1.9B | $-301.3M | ||
| Q3 24 | $1.9B | $-311.3M | ||
| Q2 24 | $2.0B | $-321.7M | ||
| Q1 24 | $2.0B | $-330.5M |
| Q4 25 | $9.9B | $396.9M | ||
| Q3 25 | $9.5B | $396.1M | ||
| Q2 25 | $9.8B | $342.9M | ||
| Q1 25 | $8.8B | $327.2M | ||
| Q4 24 | $8.4B | $350.9M | ||
| Q3 24 | $9.1B | $389.5M | ||
| Q2 24 | $9.3B | $395.6M | ||
| Q1 24 | $9.2B | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 4.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.5M | $74.6M | ||
| Q3 25 | $31.7M | $47.6M | ||
| Q2 25 | $63.2M | $-15.1M | ||
| Q1 25 | $39.3M | $20.0M | ||
| Q4 24 | $200.3M | $15.2M | ||
| Q3 24 | $47.2M | $9.9M | ||
| Q2 24 | $50.2M | $33.5M | ||
| Q1 24 | $52.8M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 4.88× | — | ||
| Q3 25 | 0.62× | 1.19× | ||
| Q2 25 | 3.05× | -0.64× | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | 4.93× | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
